Sign In
Buy TRAW
$1.45
+0.0300 (+2.11%)
At Close: Jun 03, 2026
Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program
05:55pm, Friday, 10'th Jan 2025
SAN DIEGO , Jan. 10, 2025 /PRNewswire/ -- Expert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma, Inc. 's (N
Initial tranche of $20 Million extends cash runway into 1H26, subsequent tranche of up to $52.6 Million will provide for runway 3+ years enabling the company to reach both near-term and long-term valu
Traws Pharma stock soars 200% on encouraging bird flu drug data
12:00pm, Monday, 23'rd Dec 2024
Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir marboxil as a treatment of H5N1 bird flu. The investigational drug demo
Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu
07:00am, Monday, 23'rd Dec 2024
Investigational agent in development for treatment or prevention of H5N1 Bird Flu Phase 1 dosing completed in healthy volunteers Potent inhibition of drug-resistant and bird flu viruses in vitro I
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
04:30pm, Thursday, 14'th Nov 2024
NEWTOWN, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
07:30am, Tuesday, 08'th Oct 2024
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability res
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
07:30am, Monday, 30'th Sep 2024
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
07:30am, Friday, 20'th Sep 2024
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
04:05pm, Tuesday, 17'th Sep 2024
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjust
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
09:02am, Tuesday, 20'th Aug 2024
Traws Pharma, Inc. (NASDAQ:TRAW ) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Par
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
07:00am, Thursday, 15'th Aug 2024
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clini
